Expressions of Interest are open
Inviting international teams to apply
Funding team science on a global scale
The deadline for Expressions of Interest is 22 June 2023. We’re inviting international teams to come together, think differently and take on one of our new challenges.
See below for full details on how to apply, and register your interest by 15 June.
How to apply
You can find the Expression of Interest (EOI) Guidelines here. They contain all you need to know about how to put together an EOI and what we’re looking for from applicant teams.
You will need to be registered with Cancer Research UK’s grants management system, Flexi-Grant. Visit cancerresearchuk.flexigrant.com and follow the 'Register' link.
Complete the eligibility questionnaire by 15 June 2023.
Once you’ve done so, an EOI form will be opened for you on Flexi-Grant – or a member of the Cancer Grand Challenges office team will be in touch with any questions about your answers.
Submit your EOI by 22 June 2023. The EOI will set out your vision and broad ambition for tackling your selected challenge, and detail the members of your international team.
Contact us
If you have a question, please get in touch with our team by emailing [email protected] or by calling +44 (0) 20 3469 8855. Please note, our grants office is based in the UK so responses may be slower outside of British working hours.
Key dates
Complete your eligibility questionnaire by 15 June and submit your Expression of Interest by 22 June 2023.
All EOIs will be reviewed against the assessment criteria in the guidelines, by our Cancer Grand Challenges Scientific Committee.
Up to 12 teams will be shortlisted and will receive seed funding of £30k to help them build their full applications.
Shortlisted teams will submit a 20,000 word full application by 26 October 2023.
Shortlisted teams will attend an interview with the Cancer Grand Challenges Scientific Committee on 11-13 December 2023.
Successful teams each receive up to £20m in funding to come together, think differently and take on one of cancer’s toughest challenges. See our currently funded teams.